Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations

Sally M. Hunter1, Kylie L. Gorringe1,2, Michael Christie3,4, Simone M. Rowley1, David D. Bowtell1,2, on behalf of the Australian Ovarian Cancer Study Group1,5, and Ian G. Campbell1,2

Abstract

Introduction: Mucinous tumors are the second most common form of epithelial ovarian tumor, yet the cell of origin for this histologic subtype remains undetermined. Although these tumors are thought to arise through a stepwise progression from benign cystadenoma to borderline tumor to invasive carcinoma, few studies have attempted to comprehensively characterize the genetic changes specific to this subtype or its precursors.

Methods: To explore the spectrum of genomic alterations common to mucinous tumors we carried out high-resolution genome-wide copy number analysis, mutation screening by Sanger sequencing and immunohistochemistry on a series of primary ovarian mucinous cystadenomas (n = 20) and borderline tumors (n = 22).

Results: Integration of copy number data, targeted mutation screening of RAS/RAF pathway members and immunohistochemistry reveals that p16 loss and RAS/RAF pathway alterations are highly recurrent events that occur early during mucinous tumor development. The frequency of concurrence of these events was observed in 40% of benign cystadenomas and 68% of borderline tumors.

Conclusions: This study is the largest and highest resolution analysis of mucinous benign and borderline tumors carried out to date and provides strong support for these lesions being precursors of primary ovarian mucinous adenocarcinoma. The high level of uniformity in the molecular events underlying the pathogenesis of mucinous ovarian tumors provides an opportunity for treatments targeting specific mutations and pathways. Clin Cancer Res; 18(19); 5267–77. ©2012 AACR.
Mucinous tumors are the second most common form of epithelial ovarian tumor, accounting for 36% of all epithelial ovarian tumors, 81% of which are benign cystadenomas, 14% borderline (atypical proliferative), and 5% malignant (18). Current treatments for epithelial ovarian cancers are typical across all histologies of EOC despite the known differences in characteristic molecular events between histologic groups. MOCs have been consistently reported to have lower platinum sensitivity and poorer response rates relative to other histologic types (19–22).

Thorough molecular characterization of mucinous ovarian cancers may provide opportunities for improvement of treatment options particularly if it can be shown that MOCs share molecular signatures with mucinous cancers from other organs, consistent with the overlapping histologic and clinicopathological features of mucinous cystic tumors of the ovary, pancreas, liver and retroperitoneum (23–26).

Previous studies have identified KRAS mutations as a common defect across ovarian mucinous cystadenomas, borderline tumors and carcinomas. In contrast to serous cystadenomas and cystadenofibromas in which such mutations are not observed (27–29), the rate of KRAS mutation in mucinous cystadenomas has been reported at 46% to 55% (30–32). This rate increases to 63% to 73% in borderline tumors (31, 33) and 75% to 85% in mucinous carcinomas (31, 33). This molecular evidence, combined with the presence of benign and borderline epithelium in 70% to 90% of MOCs (34–36), has provided some basis for a linear progression model for these tumors. Identification and characterization of precursor lesions can be highly informative, allowing the determination of initiating molecular events and establishing a benchmark for molecular progression models, with the potential to identify biomarkers for invasive potential. This study aimed to carry out high-resolution molecular characterization of putative precursor lesions to primary MOCs, namely mucinous cystadenomas and borderline tumors, using genome-wide copy number analysis, mutation screening and immunohistochemistry.

Materials and Methods

Tissue samples

Fresh frozen tissue samples were used for copy number and mutation analyses. All samples were collected with the patient’s informed consent and the study was approved by the Human Research Ethics Committees at the Peter MacCallum Cancer Centre. Patients with ovarian tumors were identified through 2 primary sources: (a) hospitals in the Wessex Region, UK (n = 18; ref. 37); (b) the Australian Ovarian Cancer Study (AOCs; n = 24; ref. 38). The AOCs (www.aocstudy.org) was approved by the Human Research Ethics Committees at the Peter MacCallum Cancer Centre, Queensland Institute of Medical Research, University of Melbourne and all participating hospitals. Pathology review was done independently by an anatomical pathologist (MC) for this study, and assessed the histology and likelihood of primary ovarian status (39). Pathology review was conducted on cryosections adjacent to the tissue from which DNA was extracted. Formalin-fixed paraffin embedded samples for tissue microarray (TMA) analyses were obtained through AOCs.

Microdissection and DNA extraction

A representative hematoxylin and eosin stained section was assessed and needle microdissection was done on subsequent 10-μm sections to obtain high percentage tumor epithelial cell and fibroblast cell components. DNA was extracted using the Qiagen Blood and Tissue Kit (Qiagen). Normal DNA extracted from blood lymphocytes was available for 38 patients, where this was not available matched DNA from stroma with confirmed normal copy number was used.

Copy number arrays

The AffymetrixSNP6.0 Human Mapping (1.8 M probe set) array was used for ultrahigh resolution allele-specific copy number analysis, although before its release the Affymetrix 500K array was used (samples 446, 214, and 289 only). Arrays were carried out as recommended by the manufacturer with the exception that the input was reduced from the recommended 500 to 250 ng by reducing reaction volumes by half for all processes before the SNP6.0 PCR step. Reduction in DNA input does not result in any loss in the quality of the data. MAPD scores of ≤0.4 were achieved for all samples run on the SNP6.0 platforms. All SNP data has been made publicly available through Gene Expression Omnibus GSE39076 (http://www.ncbi.nlm.nih.gov/geo/).

SNP array data were analyzed using Partek Genomics Suite 6.5, using paired and unpaired copy number generation, allele-specific copy number analysis and circular binary segmentation to identify regions of somatic copy number aberration and LOH (Supplementary Tables S4 and S5). The threshold for gains was 2.3 copies and losses 1.7
copies. Homozygous deletions (HD) were less than 0.75 copies. Regions of LOH were less than 0.5 copies of the minimum allele. Regions of CN aberration and LOH were confirmed through examination of allele-specific copy number ratios. Nexus Copy Number 6.1 Discovery Edition (BioDiscovery, Inc.) was also used for paired copy number analysis. Quadratic correction was used to smooth noise in the data, probes were centered around the median copy number, and segmentation was based on a minimum of 3 probes/segment. Default settings were used for calling copy number variation: high gain (0.7), gain (0.1), loss (−0.15), and big loss (−1.1).

**Mutation screening**

Whole genome amplified (WGA) DNA was used for mutation screening, with 50 ng of DNA amplified using the REPLI-g Mini kit (Qiagen). DNA sequencing was done by Sanger sequencing using BDT v3.1 reagents (Applied Biosystems) and an ABI3130 sequencer. Sequencing was done by Sanger sequencing using BDT v3.1 reagents (Applied Biosystems) and an ABI3130 sequencer. Sequencing was used to identify the most common ovarian tumor mutations: all samples were assessed at BRCA1/exon 11, BRCA2/exon 23, TP53 exons 4 to 9 and CDKN2A exons 1 to 3, and a subset were also tested for KRAS codons 12, 13, TP53 exons 4 to 9 and CDKN2A exons 1 to 3, and a subset were also tested for KRAS codons 61, NRAS codons 12, 13, and 61, HRAS codons 12, 13, and 61 (n = 13), and ERBB2 exon 20 (n = 23). Primer sequences are detailed in Supplementary Table S1.

**Immunohistochemistry**

TMAs were constructed by AOCS from formalin-fixed, paraffin-embedded tissues from representative 1 mm cores. Three-micrometer sections of the TMA were stained using antibodies for p16 (clone E6H4, Cintec – 9511), p53 (clone DO-7, Novocastra – NCL-p53-D07), CK7 (clone OV-TL 12/30, Dako – M7018), CK20 (clone KS20.8, Novocastra – NCL-p53-D07), and p-ERK (Cell Signaling, Cat #4370, 1/200). Three-micrometer sections of the TMA were stained using BDA v3.1 reagents (Applied Biosystems) and an ABI3130 sequencer. Sequencing was used to identify the most common ovarian tumor mutations: all samples were assessed at BRCA1/exon 11, BRCA2/exon 23, TP53 exons 4 to 9 and CDKN2A exons 1 to 3, and a subset were also tested for KRAS codons 12, 13, and 61, HRAS codons 12, 13, and 61 (n = 13), and ERBB2 exon 20 (n = 23). Primer sequences are detailed in Supplementary Table S1.

**Stromal copy number aberrations**

Stromal copy number aberrations suggestive of synchronous stromal neoplasia were identified in 3 cases (1 benign, 2 borderline), of which had chromosome 12 trisomy and the remaining case had balanced tetrasomy of chromosome 12. Chromosome 12 gain has been observed as a frequent feature across both benign and borderline mucinous tumors (27), and commonly in pure fibromas (43). HD of the CDKN2A and CDKN2B genes (Fig. 2). LOH (hemizygous deletion or copy neutral LOH) of 9p was detected in 60% of the benign tumors and in 77% of the borderline tumors. The frequency of HDs targeting CDKN2A/2B was significantly higher in borderline tumors compared with benign tumors (55% versus 20%; Fisher’s exact test P = 0.03). In our previous study of invasive MOC (40), we observed 9p LOH in 10 of 12 cases (83%), and HD in 6 of 12 cases (50%).

CNA and LOH events elsewhere in the genome were less common. Gain of chromosome 7 or 7p and LOH of chromosome 21 were observed in 4 of 22 (18.2%) and 2 of 22 (9.1%) of the borderline tumors, respectively. These CNAs were not detected in benign tumors (Table 1) but have been previously observed in invasive mucinous tumors (refs. 41, 42; Fig. 1). Other recurrent aberrations observed in benign, borderline and invasive MOTs included gain of 1q and 17q, and LOH of 17p, however, only 17p LOH was present in more than 30% of samples (in invasive cases). No CNA or LOH events were present at significantly different frequencies between benign, borderline and invasive MOT, although the power to detect such differences was limited by the small number of invasive cases available.
Deleterious CDKN2A mutations

Mutation screening was done for exons 1a-3 of CDKN2A and 4 truncating mutations and 2 frameshift mutations were identified (Tables 1 and 2); these mutations were confirmed as somatic by sequencing the matching germline DNA. These mutations were truncating only in the p16 ORF and not the ARF ORF, or targeted exon 1a (p16-specific exon), suggesting p16 is the primary target. The majority of the mutations (5/6) occurred in cases with LOH of 9p21.3 and were thus homozygous.

Oncogene activation

Mutation screening was done using Sanger sequencing for the hotspot activating mutations of KRAS, known to be frequently mutated in MOTs. Mutation screening was also done for BRAF, NRAS, HRAS, ERBB2 and TP53 (Tables 1 and 2). Consistent with previous reports, KRAS was the most commonly mutated gene in both benign and borderline MOTs, with mutation rates of 60% and 64%, respectively (Tables 1 and 2). Low rates of NRAS, BRAF and TP53 mutation were identified and no ERBB2 mutations were detected. A single case harbored a high level amplification of RRAS2, showing both an alternative oncogenic target and alternative mechanism of increasing activity. A high degree of overlap was noted between activating mutations and LOH of 9p; 50% of benign tumors with KRAS mutations also had 9p LOH, whereas 83% of borderline tumors with oncogenic mutations (KRAS, BRAF, or NRAS) also had 9p LOH (Table 3).

Immunohistochemistry analysis of p16, p53, phospho-ERK (p-ERK), CK7, and CK20

We carried out immunohistochemistry for p16, p53, phospho-ERK (p-ERK), CK7, and CK20 on a tissue microarray of 95 borderline tumors with scorable cores (Table S3) including 8 of the borderline tumors analyzed for somatic mutations described above. All 8 of these tumors were strongly positive for CK7 and negative or focally positive for CK20, supportive of their primary ovarian status. The only tumor that was TP53 mutant stained strongly for p53. Three of 4 samples with a HD of CDKN2A/2B were negative for p16 and a fourth stained weakly in 1 out of the 4 cores on the TMA.

Table 1. Genetic alterations in benign mucinous tumors

<table>
<thead>
<tr>
<th>Sample</th>
<th>9p LOH</th>
<th>Cdkn2a HD/mutations</th>
<th>Kras</th>
<th>Braf</th>
<th>Nras</th>
<th>Tp53</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>8055</td>
<td>CNLOH</td>
<td>HD</td>
<td>G12D</td>
<td>WT</td>
<td></td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>907G</td>
<td>LOH</td>
<td>HD</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>LOH 1p22.1, 7q36.1, 16p12.1-21.3, 9q</td>
</tr>
<tr>
<td>2408</td>
<td>CNLOH</td>
<td>HD</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>11142</td>
<td>LOH</td>
<td>WT</td>
<td>G12R</td>
<td>WT</td>
<td></td>
<td>WT</td>
<td>Gain 1q, 20</td>
</tr>
<tr>
<td>8676</td>
<td>CNLOH</td>
<td>WT</td>
<td>G12V</td>
<td>WT</td>
<td></td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>2845</td>
<td>LOH</td>
<td>Rs8’</td>
<td>G12V/G12D</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>2124</td>
<td>LOH</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>2124</td>
<td>LOH</td>
<td>A21-L32del</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>V157F Amp 11p15.2 (RRAS2), LOH 11p, 17p</td>
</tr>
<tr>
<td>2362</td>
<td>WT</td>
<td>P75’</td>
<td>G12A</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>3788</td>
<td>WT</td>
<td>WT</td>
<td>G12D</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>1249</td>
<td>WT</td>
<td>WT</td>
<td>G12R</td>
<td>WT</td>
<td>R175H</td>
<td>LOH 14, 17p</td>
<td></td>
</tr>
<tr>
<td>1735</td>
<td>WT</td>
<td>WT</td>
<td>G12V</td>
<td>WT</td>
<td></td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>1456</td>
<td>WT</td>
<td>WT</td>
<td>G12V</td>
<td>WT</td>
<td></td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>3045</td>
<td>WT</td>
<td>WT</td>
<td>G13E</td>
<td>WT</td>
<td></td>
<td>WT</td>
<td>Gain 1q</td>
</tr>
<tr>
<td>3335</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>3372</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
</tbody>
</table>

LOH, loss of heterozygosity = hemizygous deletion, CNLOH = copy neutral LOH. WT, wild-type.

bLikely to be a result of 2 distinct tumor cell population with KRASG12V/WT, KRASG12D/WT cells, as previously described in mucinous ovarian tumors (67).

bCo-occurring stromal copy number aberrations; gain chromosome 12.
possibly representative of tumor heterogeneity. One sample with LOH of 9p stained weakly for p16. Of the samples without LOH at CDKN2A/2B, 1 core stained positive for p16 and the other stained negative. All 8 borderline cases had KRAS mutations, however, only 4 of 8 cases were scored strongly positive for p-ERK (1 case was strongly positive in 2/4 cores), indicative of activation of the RAS/MEK/ERK pathway.

Overall, across the 95 borderline tumors on the TMA, the rate of p16 negative tumors was 65%, similar to the rates of p16 HD (55%) and p16 LOH (77%) observed in the copy number data. The rate of positive p-ERK staining across the 95 borderline cases on the TMA was 59% and was notably lower than the rates of RAS/RAF activating mutation (82%) in the 22 borderline cases screened by Sanger sequencing. P-ERK staining was found to be predominantly focal, with some heterogeneity between cores from the same tumor.

### Discussion

Genetic alterations of MOTs

Activating KRAS mutations are recognized as one of the dominant features of MOTs but we have showed that other

### Table 2. Genetic alterations in borderline mucinous tumors

<table>
<thead>
<tr>
<th>Sample</th>
<th>9p LOH</th>
<th>CDKN2A HD/mutation</th>
<th>KRAS</th>
<th>BRAF</th>
<th>NRAS</th>
<th>TPS3</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>8566</td>
<td>LOH</td>
<td>G12C</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>IC263</td>
<td>CNLOH</td>
<td>G12C</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>Gain 7, Amp 9p21.1, CNLOH 12q,17q</td>
<td></td>
</tr>
<tr>
<td>IC387</td>
<td>CNLOH</td>
<td>G12C</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>IC537</td>
<td>LOH</td>
<td>G12C</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>Gain 9q</td>
<td></td>
</tr>
<tr>
<td>5401</td>
<td>LOH</td>
<td>G12D</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>Gain 1q</td>
<td></td>
</tr>
<tr>
<td>IC289</td>
<td>CNLOH</td>
<td>G12D</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>4584</td>
<td>CNLOH</td>
<td>G12V</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>6181</td>
<td>LOH</td>
<td>G12V</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>R273C</td>
<td></td>
</tr>
<tr>
<td>4779p</td>
<td>LOH</td>
<td>G12V</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>IC531</td>
<td>CNLOH</td>
<td>G12V</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>Gain 3, 7, 5p13.1-q11.2</td>
<td></td>
</tr>
<tr>
<td>2895p</td>
<td>CNLOH</td>
<td>WT</td>
<td>V600E + indel</td>
<td>—</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>IC92</td>
<td>CNLOH</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>Gain 7p22.1-p11.2, LOH 5q11.2, 8p11.22, 20p13, CNLOH 1q</td>
<td></td>
</tr>
<tr>
<td>4691</td>
<td>CNLOH</td>
<td>R80</td>
<td>G12D</td>
<td>WT</td>
<td>—</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>4515</td>
<td>CNLOH</td>
<td>WT</td>
<td>WT</td>
<td>—</td>
<td>WT</td>
<td>Amp 17q21.3, LOH 9p23, 21, CNLOH 17q12-qter</td>
<td></td>
</tr>
<tr>
<td>4551</td>
<td>CNLOH</td>
<td>WT</td>
<td>WT</td>
<td>V600E</td>
<td>—</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>4884</td>
<td>LOH</td>
<td>K62fsV</td>
<td>WT</td>
<td>WT</td>
<td>Q61R</td>
<td>WT</td>
<td>LOH 9q33.2-9q34.12, 21</td>
</tr>
<tr>
<td>IC388</td>
<td>LOH</td>
<td>R58</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>Gain 1q, 2, 3, 6, 7p, 10, 12p, 15, 16, 17q, 18, 19q, 20, 22</td>
</tr>
<tr>
<td>528</td>
<td>WT</td>
<td>WT</td>
<td>G12C</td>
<td>WT</td>
<td>—</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>2063</td>
<td>WT</td>
<td>WT</td>
<td>G12D</td>
<td>WT</td>
<td>—</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>IC186</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>V600E</td>
<td>—</td>
<td>WT</td>
<td>Gain 7, LOH 18p11.23</td>
</tr>
<tr>
<td>11552</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
</tr>
<tr>
<td>IC322</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>WT</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

n = 22, 17 (77%) 15 (68%) 14 (64%) 3 (14%) 1 1 (5%) 10 (45%)

LOH, loss of heterozygosity = hemizygous deletion, CNLOH = copy neutral LOH. (Note: Large LOH events with co-existing focal HD was frequently observed). WT, wildtype. aBRAF c.1799G>A, 1800_1803inv, 1804-1815del; predicted to be activating based on similarity to previously reported mutation (68). bCo-occurring stromal copy number aberrations; gain chromosome 12.
members of the RAS family and pathways are also activated in these tumors. We identified mutations in \textit{BRAF} and \textit{NRAS}, whereas an alternative mechanism via high-level amplification was identified for \textit{RRAS2}. As previously reported, all oncogenic events within the RAS/RAF pathway were mutually exclusive (44–46). Over 80% of the borderline mucinous tumors had an oncogenic event, although this was not an exhaustive investigation and additional mechanisms of RAS/RAF pathway activation may occur in these tumors. Our study has also established a clear continuity of the alterations observed in benign and borderline MOTs consistent with the former being a precursor to the latter. Perhaps surprisingly, benign MOTs harbor a similar frequency of certain alterations to the borderline tumors, including numerous copy number, LOH changes and KRAS and TP53 somatic mutations indicating that many benign MOTs are poised for progression.

LOH or HD targeting 9p and 9p21.3 are early events in MOTs, occurring in 60% of benign tumors. Interestingly, the proportion of HD events relative to LOH events is significantly higher in borderline tumors (0.71) compared with benign tumors (0.33), suggesting that silencing all 3 protein products (p16\textit{INK4A} and ARF, and p15\textit{INK4B}) in this region offers a significant selective advantage. These 3 proteins have functions central to cell cycle regulation, cellular senescence, p53 regulation and apoptosis. This is consistent with the observation that elimination of the entirety of \textit{CDK2NA} (p16\textit{INK4A} and ARF) is more oncogenic in mouse models compared with loss of either p16\textit{INK4A} or ARF functions alone (47), whereas loss of both \textit{CDKN2A} and \textit{CDKN2B} is more oncogenic in mouse models than loss of \textit{CDKN2A} (p16\textit{INK4A} and ARF) alone (48).

It is unclear from these data whether oncogene activation or \textit{CDKN2A/2B} deficiency occurs first, as we observed similar numbers of benign tumors with either RAS pathway activation or p16 deficiency. In other tumor types, p16\textit{INK4A} expression has been reported to increase from benign to invasive neoplasms in an attempt to downregulate an upregulated cell-cycle program, suggesting selection for p16\textit{INK4A} inactivation may occur subsequent to oncogene activation to allow escape from oncogene-induced senescence (49–51). However, it was notable that the co-incidence of RAS activation and homozygous \textit{CDKN2A} inactivation was higher in the borderline tumors ($P = 0.06$, Fishers exact test) with only 3 of 20 benign tumors harboring both aberrations compared with 13 of 22 borderline tumors ($P = 0.005$, Fisher’s exact test). Interestingly, in our previous study of serous benign and borderline tumors (27), deletion of \textit{CDKN2A/2B} was not observed, despite a high incidence of RAS pathway activation in serous borderline tumors (~60%).

Mouse modelling of co-existing \textit{KRAS\textit{G12D}} mutations with loss of p16\textit{INK4A} activity in the mouse pancreas has showed that this combination results in aggressive
metastatic neoplasms, compared with no neoplasms or localized neoplasms with individual mutations alone (52). Intriguingly, although in the current study the vast majority of borderline MOTs carry both an oncogenic mutation and inactivated CDKN2A/2B, the low incidence of MOCs must make tumor progression even in this context quite infrequent. In the ovarian context, additional genetic or epigenetic events may be required for invasiveness. Our previous study of invasive MOC indentified additional copy number changes on several chromosomes, including 7 gain, Benign CN loss
Benign ASCN
Bordeline CN loss
Bordeline ASCN

Figure 2. CN LOH and HDs at CDKN2A are frequently observed in mucinous ovarian precursors. A, frequency plot comparing copy number (CN) loss and LOH (allele-specific copy number loss, (ASCN), including copy neutral LOH as well as HD) in benign (top) and borderline (bottom) tumors. B, zoomed view of HDs at 9p21.3 in benign and borderline tumors.

Table 3. Immunohistochemistry of selected borderline samples

<table>
<thead>
<tr>
<th>Sample</th>
<th>p16 (IHC/CN)</th>
<th>p-ERK (IHC/RAS)</th>
<th>p53 (IHC/MUT)</th>
<th>CK7</th>
<th>CK20</th>
</tr>
</thead>
<tbody>
<tr>
<td>4691</td>
<td>−/LOH</td>
<td>++/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>−</td>
</tr>
<tr>
<td>4584</td>
<td>−/HD</td>
<td>−/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>−</td>
</tr>
<tr>
<td>5401</td>
<td>−/HD</td>
<td>++/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>−</td>
</tr>
<tr>
<td>6181</td>
<td>−/HD</td>
<td>++/KRAS</td>
<td>+++/Y</td>
<td>+++</td>
<td>−</td>
</tr>
<tr>
<td>4515</td>
<td>+/LOH</td>
<td>−/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>2063</td>
<td>−/WT</td>
<td>−/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>528</td>
<td>++++/WT</td>
<td>Mixed/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>4779</td>
<td>−/HD</td>
<td>−/KRAS</td>
<td>−/N</td>
<td>+++</td>
<td>+</td>
</tr>
</tbody>
</table>

IHC, immunohistochemistry result; −, negative, + weakly or focally positive, +++ strongly or diffusely positive; HD at CDKN2A/2B; WT, no CN or LOH at CDKN2A/2B; LOH, CN loss or CNN LOH at CDKN2A/2B; MUT, mutation of p53, N, no mutation, Y, p53 mutation positive; KRAS, KRAS mutation.
8q gain, 17p LOH, and 17q gain, however, none of these were observed at a high frequency in this small cohort.

Activation of ERK1/2 (p-ERK) has been shown in cultures of transformed cells to be induced downstream of activated RAS and RAF, and is used as a functional readout for RAS/RAF/MEK/ERK pathway activation (53, 54). In this study, however, only 50% of tumors with activating KRAS mutations were found to have activated ERK1/2 by immunohistochemistry. This is consistent with studies in melanoma that found activating BRAF and NRAS mutations to have no correlation with p-ERK status (55). This study also identified a clear inverse relationship between p-ERK and p16 staining (P = 0.0007; Fisher’s Exact Test; Table 4) and a high level of overlap between activating KRAS mutations and p16 loss. Both the lack of correlation between KRAS mutation status and ERK phosphorylation, and the inverse relationship between p-ERK and p16 status can be explained by the negative regulation of KRAS expression and activity by p16 (56). When p16 is actively expressed KRAS activity is downregulated and ERK is not phosphorylated, therefore p-ERK status is dependent on and correlates with p16 status, even in the presence of an activating KRAS mutation. These data reiterate in ovarian tissues the findings of Rabien and colleagues (56) in pancreatic and colon cancer cells.

Mutations in the tumor suppressor TP53 were observed at low rates in borderline and perhaps surprisingly, in benign mucinous tumors. These mutations occurred in the context of KRAS mutation (n = 1), p16 inactivation (n = 1), or both (n = 1). In mouse models, addition of TP53 mutation has been shown to increase tumorigenicity of cells above that of either activated KRAS or inactivated p16 alone (57). TP53 mutations have been reported in 20% of invasive MOC (n = 5; ref. 58) but there is currently insufficient data to draw definitive conclusions as to whether TP53 mutation distinguishes high and low grade mucinous tumors as clearly showed for serous ovarian carcinomas.

Amplification of ERBB2 has been previously reported as relatively common in MOCs and has also been observed in mucinous borderline tumors (59, 60). No focal 17q amplification of ERBB2 was observed in any of the samples in this study. A single borderline tumor was found to carry an extra copy of the entire arm of 17q, where ERBB2 is located. Although previous reports have shown that polysomy-17 does not correlate with Her2 expression, polysomy-17 occurs more frequently in samples with ERBB2 amplification and may be a precursor aberration (61, 62). No samples were found to have ERBB2 mutations although we only focused on exon 20, which has been previously reported as an ERBB2 mutation hotspot in serous borderline ovarian tumors (63).

Cell of origin for MOTs

Extra-ovarian mucinous carcinomas have a long history of misdiagnosis as primary ovarian tumors after metastasizing to the ovary in a form highly similar to primary MOCs. These metastases may arise from a wide variety of primary sites, including the pancreas, colon, appendix, breast and lung (64, 65). In a reassessment of archival MOC cases, the majority (80%) of MOCs were reclassified as extra-ovarian in origin with only 2.4% to 4.9% retaining the classification of primary ovarian epithelial carcinoma (21, 64). Diagnosis of metastases is confounded by the tendency of some mucinous metastases to form large, cystic masses with extensive apparent benign and borderline elements known as a “maturation” phenomenon (66). In recent decades guidelines have been established to aid the diagnosis of primary and secondary carcinomas, such as size, morphology, laterality and tissue-specific immunohistochemistry (39). The majority of tumors are able to be distinguished using these features, however, these are broad guidelines and some tumors remain difficult to classify. In the cohort analyzed here, each case was reviewed using these criteria to exclude cases arising from an extra-ovarian origin. The genetic similarities between the tumors in this study and the invasive MOC studied previously (n = 12) suggest that MOC are likely to develop through a classic adenoma–borderline–carcinoma sequence within the ovary, however, a closely related pathway at an extra-ovarian site cannot be entirely excluded. None of the cases in this study had teratomatous elements reported. More MOC and extra-ovarian mucinous carcinomas need to be analyzed to evaluate these possibilities.

Conclusions

This study is the largest and highest resolution analysis of mucinous benign and borderline tumors conducted to date and provides strong support for these precursors being the origin of primary ovarian mucinous adenocarcinomas. Although a number of nonovarian potential precursors

Table 4. Staining patterns for p16 and p-ERK

<table>
<thead>
<tr>
<th></th>
<th>p16+/p-ERK</th>
<th>p16+/p-ERK</th>
<th>p16+/p-ERK</th>
<th>p16+/p-ERK</th>
<th>Fisher’s exact test</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. cases (N = 95)</td>
<td>48</td>
<td>15</td>
<td>5</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>% cases</td>
<td>53%</td>
<td>17%</td>
<td>5.60%</td>
<td>24%</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Five cases had either inverse staining patterns within the cores (n = 3) or ambiguous staining patterns (n = 2).

BL, borderline; CK, cytokeratin; CN, copy number; CNA, copy number aberrations; CN LOH, copy neutral LOH; EOC, epithelial ovarian carcinoma; HGSC, high grade serous carcinoma; IHC, immunohistochemistry; LOH, loss of heterozygosity; MOC, mucinous ovarian carcinoma; MOT, mucinous ovarian tumor; TMA, tissue microarray.
have been postulated, no bona fide alternative precursor has been identified for the majority of benign or borderline MOTs, and mucinous tumors may remain as the only true primary ovarian tumors. Current data does not, however, preclude the possibility that benign mucinous epithelial cells undergo migration from an unknown primary location to the ovary, which may provide an ideal niche for growth and tumorigenesis. The high level of uniformity in the molecular events underlying the pathogenesis of MOTs provides an opportunity for treatments targeting specific mutations and pathways. Further molecular characterization is required to determine whether molecular events can be identified that can distinguish between mucinous tumors of ovarian and extra-ovarian origin.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: S.M. Hunter, K.L. Gorringe, I.G. Campbell
Development of methodology: M. Christie, I.G. Campbell
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.M. Hunter, D.D. Bowtell, I.G. Campbell

References

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.M. Hunter, K.L. Gorringe, M. Christie, I.G. Campbell
Writing, review, and/or revision of the manuscript: S.M. Hunter, K.L. Gorringe, M. Christie, D.D. Bowtell, I.G. Campbell
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.M. Rowley, I.G. Campbell
Study supervision: I.G. Campbell

Acknowledgments
We would like to thank Kelly Waldeck for her expertise and assistance in performing the phospho-ERK IHC staining.

Grant Support
This study was supported by the Victorian Breast Cancer Research Consortium (VBCRC) and the National Health & Medical Research Council of Australia (NHMRC; ID 628630) and the Emer Casey Foundation. The AOCS was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Tasmania and The Cancer Foundation of Western Australia and the National Health and Medical Research Council of Australia (NHMRC; ID 400413). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 3, 2012; revised July 4, 2012; accepted August 5, 2012; published OnlineFirst August 13, 2012.
Hunter et al.


Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations

Sally M. Hunter, Kylie L. Gorringe, Michael Christie, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-1103

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/08/13/1078-0432.CCR-12-1103.DC1

Cited articles
This article cites 67 articles, 15 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/19/5267.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.